Tonix Pharmaceuticals Holding Corp. Statistics
Share Statistics
Tonix Pharmaceuticals Holding Corp. has 186.89M shares outstanding. The number of shares has increased by 131.26% in one year.
| Shares Outstanding | 186.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 36.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 186.89M |
| Failed to Deliver (FTD) Shares | 52.46K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 7.67M, so 4.1% of the outstanding shares have been sold short.
| Short Interest | 7.67M |
| Short % of Shares Out | 4.1% |
| Short % of Float | 4.1% |
| Short Ratio (days to cover) | 0.35 |
Valuation Ratios
The PE ratio is -0.06 and the forward PE ratio is null.
| PE Ratio | -0.06 |
| Forward PE | null |
| PS Ratio | 0.88 |
| Forward PS | 1.5 |
| PB Ratio | 0.07 |
| P/FCF Ratio | -0.06 |
| PEG Ratio | n/a |
Enterprise Valuation
Tonix Pharmaceuticals Holding Corp. has an Enterprise Value (EV) of -8.27M.
| EV / Earnings | 0.07 |
| EV / Sales | -1.06 |
| EV / EBITDA | 0.07 |
| EV / EBIT | 0.07 |
| EV / FCF | 0.08 |
Financial Position
The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.53 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.79 |
| Cash Flow / Debt | -11.45 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.11% and return on capital (ROIC) is -102.64%.
| Return on Equity (ROE) | -1.11% |
| Return on Assets (ROA) | -0.76% |
| Return on Capital (ROIC) | -102.64% |
| Revenue Per Employee | 75.42K |
| Profits Per Employee | -1.13M |
| Employee Count | 103 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.34 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -97.31% in the last 52 weeks. The beta is 2.08, so Tonix Pharmaceuticals Holding Corp.'s price volatility has been higher than the market average.
| Beta | 2.08 |
| 52-Week Price Change | -97.31% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 50.09 |
| Average Volume (20 Days) | 100.01M |
Income Statement
In the last 12 months, Tonix Pharmaceuticals Holding Corp. had revenue of 7.77M and earned -116.66M in profits. Earnings per share was -219.09.
| Revenue | 7.77M |
| Gross Profit | 3.03M |
| Operating Income | -118.38M |
| Net Income | -116.66M |
| EBITDA | -114.09M |
| EBIT | -118.38M |
| Earnings Per Share (EPS) | -219.09 |
Balance Sheet
The company has 24.95M in cash and 9.81M in debt, giving a net cash position of 15.13M.
| Cash & Cash Equivalents | 24.95M |
| Total Debt | 9.81M |
| Net Cash | 15.13M |
| Retained Earnings | -600.66M |
| Total Assets | 94.99M |
| Working Capital | 35.36M |
Cash Flow
In the last 12 months, operating cash flow was -102.00M and capital expenditures -7.89M, giving a free cash flow of -109.90M.
| Operating Cash Flow | -102.00M |
| Capital Expenditures | -7.89M |
| Free Cash Flow | -109.90M |
| FCF Per Share | -206.39 |
Margins
Gross margin is 3.90K%, with operating and profit margins of -152.39K% and -150.18K%.
| Gross Margin | 3.90K% |
| Operating Margin | -152.39K% |
| Pretax Margin | -150.18K% |
| Profit Margin | -150.18K% |
| EBITDA Margin | -1.47K% |
| EBIT Margin | -1.52K% |
| FCF Margin | -1.41K% |
Dividends & Yields
TNXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -68465.62% |
| FCF Yield | -184.62% |
Analyst Forecast
The average price target for TNXP is $53.5, which is 16618.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.5 |
| Price Target Difference | 16618.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 10, 2024. It was a backward split with a ratio of 1:32.
| Last Split Date | Jun 10, 2024 |
| Split Type | backward |
| Split Ratio | 1:32 |
Scores
| Altman Z-Score | -10.63 |
| Piotroski F-Score | 3 |